We are live on
!
Find out more
Boston Partners Portfolio holdings
AUM
$95.5B
1-Year Est. Return
28.4%
This Fund
S&P 500
This Quarter
Est. Return
+1.76%
1 Year Est. Return
+28.4%
3 Year Est. Return
+84.58%
5 Year Est. Return
+116.72%
10 Year Est. Return
+426.49%
AUM
$82.7B
AUM Growth
+$473M
(+0.58%)
Cap. Flow
+$823M
Cap. Flow
% of AUM
0.99%
Top 10 Holdings %
Top 10 Hldgs %
14.9%
Holding
783
New
76
Increased
301
Reduced
323
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coca-Cola
KO
|
+$598M |
| 2 |
Apollo Global Management
APO
|
+$418M |
| 3 |
Allstate
ALL
|
+$416M |
| 4 |
SCHW
Charles Schwab
SCHW
|
+$385M |
| 5 |
Quest Diagnostics
DGX
|
+$377M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$431M |
| 2 |
Delta Air Lines
DAL
|
+$318M |
| 3 |
Deere & Co
DE
|
+$282M |
| 4 |
Robert Half
RHI
|
+$270M |
| 5 |
Curtiss-Wright
CW
|
+$265M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 21.07% |
| 2 | Technology | 14.6% |
| 3 | Industrials | 13.72% |
| 4 | Healthcare | 11.92% |
| 5 | Consumer Discretionary | 8.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Crane NXT
CXT
$3.1B
| $1.44M | ﹤0.01% |
28,062
+5,749
| +26% | +$337K |
|
527
AllianceBernstein
AB
$3.54B
| $1.44M | ﹤0.01% |
37,622
-1,167
| -3% | -$43.9K |
|
528
Warrior Met Coal
HCC
$4.19B
| $1.4M | ﹤0.01% |
29,280
+7,562
| +35% | +$386K |
|
529
Jazz Pharmaceuticals
JAZZ
$16.3B
| $1.38M | ﹤0.01% |
11,150
+1,978
| +22% | +$258K |
|
530
Open Text
OTEX
$6B
| $1.37M | ﹤0.01% |
54,157
+7,605
| +16% | +$209K |
|
531
Constellium
CSTM
$3.99B
| $1.37M | ﹤0.01% |
135,436
+4,164
| +3% | +$44.3K |
|
532
DHT Holdings
DHT
$2.98B
| $1.35M | ﹤0.01% |
128,811
-39,193
| -23% | -$422K |
|
533
First Bancorp
FBP
$4.44B
| $1.35M | ﹤0.01% |
70,424
+2,165
| +3% | +$42.1K |
|
534
Hamilton Insurance Group
HG
$3.68B
| $1.34M | ﹤0.01% |
64,563
+3,382
| +6% | +$66K |
|
535
Boston Scientific
BSX
$69B
| $1.34M | ﹤0.01% |
13,235
+116
| +0.9% | +$11.7K |
|
536
Pure Cycle
PCYO
$262M
| $1.32M | ﹤0.01% |
125,781
-3,049
| -2% | -$34.6K |
|
537
Leonardo DRS
DRS
$13B
| $1.27M | ﹤0.01% |
38,735
+1,149
| +3% | +$37.9K |
|
538
Phreesia
PHR
$663M
| $1.25M | ﹤0.01% |
49,054
-8,046
| -14% | -$219K |
|
|
539
Delta Air Lines
DAL
$58.6B
| $1.24M | ﹤0.01% |
28,458
-5,364,134
| -99% | -$318M |
|
540
ICL Group
ICL
$6.78B
| $1.23M | ﹤0.01% |
216,950
-39,686
| -15% | -$234K |
|
|
TGB
541
Trekor Metals
TGB
$2.52B
| $1.22M | ﹤0.01% |
544,560
-61,639
| -10% | -$131K |
|
542
Best Buy
BBY
$19B
| $1.22M | ﹤0.01% |
+16,566
| New | +$1.37M |
|
543
TSMC
TSM
$2.03T
| $1.21M | ﹤0.01% |
7,270
-58,296
| -89% | -$11.3M |
|
544
Ferguson
FERG
$44.8B
| $1.18M | ﹤0.01% |
7,393
-540,372
| -99% | -$93.7M |
|
545
New Jersey Resources
NJR
$6.1B
| $1.17M | ﹤0.01% |
23,918
+7,614
| +47% | +$361K |
|
546
Vermilion Energy
VET
$1.57B
| $1.16M | ﹤0.01% |
143,769
-57,032
| -28% | -$509K |
|
547
Heritage Insurance Holdings
HRTG
$899M
| $1.15M | ﹤0.01% |
79,506
+3,109
| +4% | +$37.4K |
|
548
Lifeway Foods
LWAY
$471M
| $1.14M | ﹤0.01% |
46,804
+1,804
| +4% | +$40.5K |
|
549
SM Energy
SM
$7.04B
| $1.14M | ﹤0.01% |
38,085
+8,475
| +29% | +$304K |
|
550
iShares Russell Mid-Cap Value ETF
IWS
$15.8B
| $1.13M | ﹤0.01% |
9,060
-4,485
| -33% | -$584K |
|
Similar funds
Boston Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Boston Partners held 783 positions worth $82.7B, up 0.58% from $82.2B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Boston Partners's Q1 2025 filing shows 76 new, 301 increased, 323 reduced and 81 closed positions. Its largest new stake was Coca-Cola: 8,951,766 shares worth $642M. The largest sale was Amgen, an estimated $431M.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 21% a quarter earlier, followed by Technology and Industrials.
- Boston Partners's largest Q1 2025 buy was Coca-Cola: 8,951,766 shares worth $642M.
- Boston Partners added most to Allstate in Q1 2025, an estimated $416M increase.
- Boston Partners's biggest Q1 2025 reduction was Amgen, cutting an estimated $431M.
- Boston Partners fully exited Hologic in Q1 2025, selling an estimated $258M.
- Boston Partners's ten largest holdings make up 15% of its $82.7B portfolio in Q1 2025.
- Boston Partners opened 76 new positions and closed 81 in Q1 2025.
- Boston Partners's portfolio value rose 0.58% quarter-over-quarter to $82.7B.
Based on Boston Partners's 13F filing for Q1 2025, filed 13 May 2025.